Bimatoprost (Lumigan) je analog prostaglandina. On je prolek koji se koristi topikalni (u obliku kapi za oči) za kontrolu progresa glaukoma i okularne hipertenzije. On redukuje intraokularni pristisak (IOP) putem povećanja odliva fluida iz očiju.[5] Poznato je da se koristi za produžavanje trepavica.[6]FDA je odobrila ovaj način primene decembra 2008. Kozmetička formulacija bimatoprosta je u prodaji pod imenom Latis.[7] Tokom perioda od 2008 - 2011, utvrđeno je da bimatoprost ima sposobnost redukovanja masnog tkiva.[8][9][10]
↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry4: 217–241. doi:10.1016/S1574-1400(08)00012-1.
↑Park J, Cho HK, Moon JI (2011). "Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost.". Japanese Ophthalmological Society55 (1): 22–27. PMID21331688. doi:10.1007/s10384-010-0904-z.
↑Jayaprakasam A, Ghazi-Nouri S. (2010). "Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues.". Orbit29 (6): 357–359. PMID21158579. doi:10.3109/01676830.2010.527028.
↑Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. (2008). "Periorbital changes associated with topical bimatoprost.". Ophthalmology Plastic and Reconstructive Surgery24 (4): 302–307. PMID18645437. doi:10.1097/IOP.0b013e31817d81df.
Chen M, Cheng C, Chen Y, Chou C, Hsu W (2006). "Effects of bimatoprost 0.03% on ocular hemodynamics in normal tension glaucoma.". J Ocul Pharmacol Ther22 (3): 188–93. PMID16808680. doi:10.1089/jop.2006.22.188.
Kruse P, Rieck P, Sherif Z, Liekfeld A (2006). "Cystoid macular edema in a pseudophakic patient after several glaucoma procedures. Is local therapy with bimatoprost the reason?". Klinische Monatsblätter für Augenheilkunde223 (6): 534–7. PMID16804825. doi:10.1055/s-2005-858992.
Steinhäuser S (2006). "Decreased high-density lipoprotein serum levels associated with topical bimatoprost therapy.". Optometry77 (4): 177–9. PMID16567279. doi:10.1016/j.optm.2006.02.001.
Park J, Cho HK, Moon JI (2011). "Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost.". Japanese Ophthalmological Society55 (1): 22–27. PMID21331688. doi:10.1007/s10384-010-0904-z.
Jayaprakasam A, Ghazi-Nouri S. (2010). "Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues.". Orbit29 (6): 357–359. PMID21158579. doi:10.3109/01676830.2010.527028.
Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. (2008). "Periorbital changes associated with topical bimatoprost.". Ophthalmology Plastic and Reconstructive Surgery24 (4): 302–307. PMID18645437. doi:10.1097/IOP.0b013e31817d81df.